Skip to main content

Table 2 Mean, standard deviations and 95% C.I. of main headache features in migraine patients with and without fibromyalgia (FM) comorbidity. Standard deviations and 95% CI are reported in brackets

From: Efficacy of monoclonal antibodies against CGRP in migraine patients with fibromyalgia comorbidity: a retrospective monocentric observational study

 

Group

Mean (SD, 95% C.I.)

Statistical analysis (ANOVA)

Headache frequency

 T0

FM

no FM

19.31 (7.70, 16.2- 22.4)

18.21 (7.37, 16.7–19.7)

T0 vs T1

F 96.6 p 0.001

 T1

FM

no FM

11.42 (8.14, 8.13- 14,7)

9.81 (7.69, 8.23–11.4)

T0 vs T1 x FM vs no FM

F0.083 p 0.77

Days with rescue therapy

 T0

FM

NoFM

17.62 (6.74, 14.9–20.3)

17.02 (7.82, 15.4–18.6)

T0 vs T1

F 106 p 0.001

 T1

FM

no FM

9.73 (6.71,7.02–12.04)

7.94 (7.38, 6.42–9.45)

T0 vs T1 x FM vs noFM

F 0.42 p 0.48

Headache intensity

 T0

FM

no FM

8.88(1.31, 8.36–9.41)

9.29 (1.12,9.06–9.52)

T0 vs T1

F 89.75 p 0.001

 T1

FM

no FM

7.46 (1.90, 6.69–8.23)

6.97 (1.84,6.59–7.34)

T0 vs T1 x FM vs no FM

F 5.24 p 0.024

MIDAS

 T0

FM

NoFM

62.81(25.97,52.3–73.3)

58.73(30.11,52.6–64.8)

T0 vs T1

F 65 p 0.001

 T1

FM

no FM

36.19(19.15,28.5–43.9)

29.71(26.73,24.2–35.2)

T0 vs T1 x FM vs. noFM

F 0.1 p 0.74

  1. Results of ANOVA for repeated measures are shown, with significant results reported in bold